PT - JOURNAL ARTICLE AU - Eugenia-Toledo-Romani, Maria AU - Verdecia-Sánchez, Leslihana AU - Rodriguez-González, Meybis AU - Rodríguez-Noda, Laura AU - Valenzuela-Silva, Carmen AU - Paredes-Moreno, Beatriz AU - Sanchez-Ramirez, Belinda AU - Perez-Nicado, Rocmira AU - González-Mugica, Raul AU - Hernández-Garcia, Tays AU - Bergado-Baez, Gretchen AU - Pi-Estopiñán, Franciscary AU - Cruz-Sui, Otto AU - Fraga-Quintero, Anitza AU - García-Montero, Majela AU - Palenzuela-Diaz, Ariel AU - Baro-Roman, Gerardo AU - Mendosa-Hernández, Ivis AU - Fernandez-Castillo, Sonsire AU - Climent-Ruiz, Yanet AU - Santana-Mederos, Darielys AU - Gonzalez, Ubel Ramírez AU - García-Vega, Yanelda AU - Perez-Massón, Beatriz AU - Guang-Wu-Chen, AU - Boggiano-Ayo, Tammy AU - Ojito-Magaz, Eduardo AU - Rivera, Daniel G. AU - Valdés-Balbín, Yury AU - García-Rivera, Dagmar AU - Vérez-Bencomo, Vicente AU - , TI - Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme AID - 10.1101/2021.11.14.21266309 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.14.21266309 4099 - http://medrxiv.org/content/early/2021/11/15/2021.11.14.21266309.short 4100 - http://medrxiv.org/content/early/2021/11/15/2021.11.14.21266309.full AB - Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric-RBD. Here we report safety, reactogenicity and immunogenicity from phase I and IIa clinical trials using two-doses SOBERANA 02 (homologous protocol) and three-doses (homologous) or heterologous (with SOBERANA Plus) protocols.Method We performed an open-label, monocentric, sequential and adaptive phase I for evaluating safety, reactogenicity and exploring immunogenicity of SOBERANA 02 in two formulations (15 and 25 μg) in 40 subjects, 19–59 years old. Phase IIa was open-label including 100 volunteers 19–80 years, receiving two doses of SOBERANA 02-25 μg. In both trials, half of volunteers received a third dose of SOBERANA 02, half received a heterologous dose of SOBERANA Plus-50 μg. Primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity evaluated by anti-RBD IgG ELISA, molecular neutralization test of RBD:hACE2 interaction, live-virus neutralization test and specific T-cells response.Results The most frequent AE was local pain, other AEs had frequencies ≤ 5%. No serious related AEs were reported. Phase IIa confirmed the safety results in 60–80 years subjects. In phase-I SOBERANA 02-25µg elicited higher immune response than SOBERANA 02-15 µg; in consequence, the higher dose progressed to phase IIa. Phase IIa results confirmed the immunogenicity of SOBERANA 02-25 μg even in 60–80 age range. Two doses of SOBERANA02-25 μg elicited an immune response similar to that of the Cuban Convalescent Serum Panel; it was higher after both the homologous and heterologous third doses; the heterologous scheme showing a higher immunological response.Conclusions SOBERANA 02 was safe and immunogenic in persons aged 19–80 years, eliciting neutralizing antibodies and specific T cell response. Highest immune responses were obtained in the heterologous three doses protocol. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000340 and https://rpcec.sld.cu/trials/RPCEC00000347Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRPCEC00000340 and RPCEC00000347Funding StatementThis study was supported by the Finlay Vaccine Institute, BioCubaFarma and the National Fund for Science and Technology, (FONCI-CITMA-Cuba, contract 2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Phase I clinical trial was approved by the Ethical Committee at the Cuban National Centre for Toxicology; phase IIa was approved by a Research Ethic Committee from the Medical Sciences University, Faculty of Medicine Manuel Fajardo, Havana, designed by the Health Innovation Committee from the Cuban Ministry of Health (MINSAP). The Cuban National Regulatory Agency (Centre for State Control of Medicines and Medical Devices, CECMED) approved the trials and the procedures (CECMED, Authorizations dates: 29th October, 2020 for phase 1, Reference number: 05.014.20BA, and 17th December for phase 2, Reference number: 05.019.20BA). Independent Data Monitoring Committees formed by external members (four in phase I and six in phase II committees) specialized on clinical practice, epidemiology and statistics were in charge of interim analysis of safety and immunogenicity. Three interim data analyses were done after first and second doses; satisfactory results allowed phase II trial authorization, incorporating elderly participants. The final data analysis was done 28 days post third immunization. The Cuban National Centre for the Coordination of Clinical Trials (CENCEC) was responsible for monitoring the trial in terms of adherence to the protocol, Good Clinical Practice and data accuracy. Both trials were conducted according to Helsinki Declaration, Good Clinical Practice and the Cuban National Immunization Program. During recruitment, the investigators provided the potential participants with oral and written information about the vaccine candidates and trial potential risks and benefits. Written informed consent was obtained from all participants. The decision to participate was voluntary and was not remunerated. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.finlay.edu.cu/blog/category/sala-cientifica/